Mice were treated with PEGSerp-1 beginning at 4 weeks old, concomitant with symptom onset in this mouse model of DMD [46,47]; however, this indicates that muscle damage has occurred already, and future studies will need to use an alternative delivery method of the Serp-1 protein at younger ages in order to truly determine the long-term outcomes and efficacy. Here, SERP1 is linked to Duchenne muscular dystrophy.